Trial ID or NCT#

NCT03126916

Status

recruiting iconRECRUITING

Purpose

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Official Title

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Eligibility Criteria

Ages Eligible for Study: 365 Days to 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Jay Michael S. Balagtas
Sheri Spunt

Contact us to find out if this trial is right for you.

CONTACT

Richard Fu
(650) 497-8815